ea0098t1 | Trials In Progress | NANETS2023
Hope Thomas A.
, Halperin Daniel
, Strosberg Jonathan
, Jacene Heather
, E.T. Tesselaar Margot
, Kunz Pamela L.
, Ferreira Denis
, Li Joanne
, Ma Kimberly
, Rearden Jessica
, Moran Susan
, Singh Simron
Background: Well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are commonly characterized by high-density expression of somatostatin receptors (SSTRs), which can be targeted by radiopharmaceutical therapy (RPT) via radiolabeled somatostatin analogues (SSAs). RYZ101 (225Ac-DOTATATE) is a first-in-class, highly potent alpha-emitting RPT being developed for the treatment of SSTR+ solid tumors. Alpha-particles (such as those emitted by 225<...